Regeneron Pharmaceuticals is a fully integrated biotechnology company that generated $14.3 billion in revenue in 2025 by discovering and commercializing medicines for serious diseases including retinal conditions, Type 2 inflammation, and cancer. Founded in 1988 by physician-scientists Leonard Schleifer and George Yancopoulos, the company employs over 15,400 colleagues and maintains a $66 billion market capitalization while investing 41% of revenue in research and development.
Regeneron Pharmaceuticals: Key Facts
- Founded: 1988 in Tarrytown, New York
- Headquarters: Tarrytown, New York
- CEO: Leonard S. Schleifer, M.D., Ph.D.
- Revenue (FY2025): $14.3 billion
- Employees: 15,410 across 12 countries
- Primary Products: EYLEA (ophthalmology), Dupixent (immunology), Libtayo (oncology)
How Does Regeneron Pharmaceuticals Make Money?
Regeneron generates revenue through a hybrid model of direct U.S. product sales and international profit-sharing collaborations. In fiscal year 2024, the company recorded $14.202 billion in total revenue, with U.S. net product sales of EYLEA and EYLEA HD contributing $5.97 billion (42% of total), Sanofi collaboration revenue for Dupixent and other antibodies contributing $4.53 billion (32%), and Bayer collaboration revenue for ex-U.S. EYLEA sales contributing $1.50 billion (10.5%). The EYLEA franchise, including the original 2mg formulation and the high-dose 8mg HD version approved in 2023, is sold directly to U.S. wholesalers and specialty distributors, with Besse Medical and McKesson Corporation accounting for 74% of gross product revenue. Dupixent, the IL-4Rα blocker for atopic dermatitis, asthma, COPD, and other Type 2 inflammatory diseases, is commercialized globally by Sanofi, with Regeneron receiving a 27% profit share that generated $3.92 billion in 2024 and $5.24 billion in 2025. Libtayo, the PD-1 inhibitor for skin and lung cancers, generated $1.45 billion in global sales in 2025 after Regeneron reclaimed full worldwide rights from Sanofi in 2022. The company also records smaller but growing revenue from Praluent in cardiovascular disease, Kevzara in rheumatoid arthritis, and the newly approved DB-OTO gene therapy for congenital hearing loss.
Who Founded Regeneron Pharmaceuticals and When?
Regeneron Pharmaceuticals was founded in 1988 by Leonard S. Schleifer, M.D., Ph.D., a neurologist trained at the University of Virginia and Johns Hopkins, and George D. Yancopoulos, M.D., Ph.D., an immunologist trained at Columbia University and the NIH. The two physician-scientists established the company in a converted industrial laboratory in Tarrytown, New York, with initial funding from venture capital firms and the mentorship of former Merck CEO P. Roy Vagelos. Both co-founders remain in active leadership today as board co-chairs, with Schleifer serving as CEO and Yancopoulos as Chief Scientific Officer, making Regeneron the only large-cap biotechnology company still under original founder control after 37 years. The company's founding mission was to develop neurotrophic factors for neurodegenerative diseases, though the failure of the lead ciliary neurotrophic factor program in 1995 forced a pivot to antibody platform technologies that would eventually produce 15 approved medicines.
What Is Regeneron Pharmaceuticals' Competitive Advantage?
Regeneron's primary competitive advantage is the VelocImmune platform, a proprietary genetically humanized mouse technology that produces fully human antibodies and bispecific antibodies with optimized therapeutic properties. Unlike competitors who rely on phage display or humanization of murine antibodies, VelocImmune mice contain megabase-scale human immunoglobulin gene insertions that generate diverse, natural antibody repertoires, enabling the discovery of 15 approved medicines with a success rate that far exceeds industry averages. The second competitive advantage is the Regeneron Genetics Center, which has sequenced over 3 million exomes and identified protective loss-of-function variants that directly validate therapeutic targets before expensive clinical trials begin, as demonstrated by the ANGPTL3 discovery that led to Evkeeza and the GPR75 target now in development for obesity. The third advantage is the co-leadership of Schleifer and Yancopoulos, who have maintained scientific control over pipeline decisions for 37 years, preventing the commercial dilution common at biotech firms that hire external CEOs. The fourth advantage is manufacturing expertise in complex biologics, with internal production facilities in Rensselaer, New York and Limerick, Ireland, supplemented by a $3 billion partnership with FUJIFILM Diosynth. Together, these advantages create a 5-10 year replication barrier that competitors cannot overcome through hiring or acquisition alone.
How Has Regeneron's Revenue Grown Over Time?
Regeneron's revenue has grown from zero in 1988 to $14.3 billion in 2025, with the inflection point occurring in 2011 when the FDA approved EYLEA for wet age-related macular degeneration. Revenue reached $2.3 billion in 2013, $4.1 billion in 2015, $13.1 billion in 2023, $14.2 billion in 2024, and $14.3 billion in 2025. The 2024-2025 growth of only 1% reflects the maturation of the EYLEA franchise, which declined 27% in U.S. sales during 2025 due to biosimilar competition, offset by 26% growth in Dupixent global sales and 20% growth in Libtayo. The company's five-year compound annual growth rate from 2020 to 2025 is approximately 12%, driven primarily by Dupixent's indication expansion across dermatology, asthma, and COPD. Profit margins have remained consistently above 28%, with net income reaching $4.41 billion in 2024 and diluted earnings per share growing from $34.77 in 2023 to $38.34 in 2024. The revenue composition has shifted from 100% EYLEA in 2012 to a diversified portfolio where EYLEA contributes 31%, Dupixent profit share contributes 37%, and other products contribute 32% as of 2025.
Regeneron Pharmaceuticals Business Model Explained
Regeneron operates a fully integrated biotechnology business model that combines proprietary drug discovery, internal manufacturing, and hybrid commercialization through direct U.S. sales and international collaborations. The discovery engine is powered by VelocImmune, Veloci-8i2, and the Regeneron Genetics Center, which together produce clinical candidates at a rate of 2-3 per year with industry-leading success rates. Manufacturing is conducted at company-owned facilities and through the FUJIFILM Diosynth partnership, with quality control systems that support FDA, EMA, and Japanese PMDA inspections. Commercialization in the United States is handled by a direct sales force of over 500 representatives specializing in ophthalmology, immunology, and oncology, while international markets are served through profit-sharing arrangements with Sanofi for immunology and Bayer for ophthalmology. The collaboration model allows Regeneron to capture 27-39% of global profits without building commercial infrastructure in 100+ countries, though it creates accounting complexity and partner dependency. Research and development spending of $5.9 billion in 2025, representing 41% of revenue, funds nearly 50 clinical candidates including 18 late-stage programs, with the company's scientific culture prioritizing mechanism-driven target selection over market-size estimates. This integrated model has produced 15 approved medicines, nearly all discovered internally, and has sustained profit margins above 28% while reinvesting at levels that exceed every large-cap pharmaceutical peer.
Regeneron Pharmaceuticals Key Acquisitions
Regeneron has pursued a selective acquisition strategy focused on new modalities rather than marketed products. In September 2023, the company acquired Decibel Therapeutics for approximately $109 million, adding three gene therapy programs for congenital hearing loss including DB-OTO, which received FDA approval in 2025 as the first gene therapy for otoferlin-related deafness. In 2024, Regeneron acquired 2seventy bio's cell therapy platforms for a $5 million upfront payment, forming Regeneron Cell Medicines with 150 transferred employees to advance CAR-T and TCR therapies in oncology and immunology. In 2022, the company acquired Checkmate Pharmaceuticals for approximately $250 million to deepen its immuno-oncology portfolio with a TLR9 agonist approach. These acquisitions reflect a strategic shift beyond monoclonal antibodies into genetic medicines and cell therapy, funded by the company's $18.87 billion cash position and disciplined capital allocation. Unlike pharmaceutical conglomerates that acquire revenue, Regeneron acquires platforms and capabilities that complement its existing scientific infrastructure, with each transaction sized to minimize dilution while providing optionality on emerging therapeutic modalities.
What Are the Biggest Risks Facing Regeneron Pharmaceuticals?
The biggest risks facing Regeneron are the erosion of its two revenue pillars and the lack of near-term pipeline diversification. EYLEA faces FDA-approved biosimilars that have already caused a 27% decline in U.S. sales during 2025, and while EYLEA HD is growing at 36% annually, it has not offset the original formulation's decline. Dupixent's composition of matter patents expire in the late 2020s and early 2030s, threatening the $5.24 billion annual profit share from Sanofi. Customer concentration risk is extreme, with Besse Medical and McKesson accounting for 74% of gross product revenue, meaning inventory adjustments could swing quarterly results by hundreds of millions. The pipeline contains no confirmed blockbuster capable of replacing the $10 billion combined economic contribution of EYLEA and Dupixent, with late-stage candidates like odronextamab and itepekimab facing competitive markets already populated by established therapies. Finally, the company's heavy dependence on Sanofi and Bayer for 42% of revenue creates partner-dependent commercial and regulatory risks that are outside Regeneron's direct control.
Bottom Line
Regeneron Pharmaceuticals is a growing but maturing biotechnology company facing a critical transition period. Revenue grew 1% in 2025 to $14.3 billion, with Dupixent's 26% global sales growth and Libtayo's 19% growth offsetting EYLEA's 27% U.S. decline. The company maintains extraordinary profitability with 30% net margins and $18.87 billion in cash, providing the financial capacity to fund its $6.6 billion 2026 R&D budget and pursue genetic medicines, cell therapy, and obesity programs. However, the concentration of 80% of revenue in two franchises facing biosimilar and patent cliff risks means that the 2025-2028 period will determine whether Regeneron can diversify into a multi-product biotechnology company or remains dependent on the EYLEA-Dupixent duopoly that has defined its first decade of profitability.
